The Ayad laboratory focuses on identifying therapeutic combinations for cancer or neuroscience indications. To identify novel therapeutic targets, transcriptomic or proteomic databases are analyzed, and novel computational platforms are developed for the most common malignant pediatric brain tumor medulloblastoma, or the adult brain tumor glioblastoma. Subsequently, collaborations with medicinal chemists yields drug-like compounds that are developed into clinical candidates. In addition, existing drugs or immunotherapies are also analyzed as candidates for clinical trials in collaborations with colleagues in The Lombardi Comprehensive Cancer Center Consortium.
Academic Appointment(s)
- Secondary
- Professor, Department of Oncology